Familial Nasopharyngeal Carcinoma 6

Screening and Early Diagnosis of Nasopharyngeal Carcinoma 59Table 5.1. (cont.) Sensitivity and specificity of various antibodies against Epstein–Barr virus for screening of nasopharyngealcarcinomaAuthor and year Area Case and controls Method ResultLeung et al. (2004) Hong-Kong 139 NPC cases178 healthy controlsChan et al. (2003) Hong-Kong 218 samples51 NPC + 4 LELCof the lung23 other cancer + 140did not have tumorCheng et al. (2002)Hong-Kongand Zhongshan121 NPC cases332 healthycontrolsConnolly et al. (2001) China 52 NPC cases52 nonNPC patientsmatched by ageand genderFeng et al. (2001) Singapore 51 NPC cases115 nonNPC ENTcontrolsHsu et al. (2001) Taiwan 123 NPC cases149 nonNPC ENTcontorlsLiu et al. (1997) Taiwan 100 NPC outpatients7 pre-NPC patientsVCA IgA (FA)EBV DNA (PCR)VCA IgA (FA)EA IgA (FA)EBNA1 IgA (ELISA)Zta IgG (ELISA)EBV DNA (PCR)EBNA1 IgG (ELISA)EBNA1 IgA (ELISA)Zta IgG (ELISA)VCA IgA (FA)TK(ELISA)VCA IgA (FA)EA IgA (FA)Rta (ELISA)VCA IgA (FA)EA IgA (FA)VCA IgA (FA)VCA IgG (FA)EA IgA (FA)EA IgG (FA)EA + EBNA1IgA (ELISA)VCA IgA (FA)DNAse (NT and ELISA)MDBP (ELISA)DP (NT)VCA IgASen: 81% Spe: 98%DNA (≥60 copies/ml)Sen: 95% Spe: 96%Combined marker panel:Sen: 99%VCA IgA (1:40)Sen: 93% Spe: 60%EA IgA (1:10)Sen: 73% Spe: 97%EBNA1 IgASen: 84% Spe: 87%Zta IgGSen: 75% Spe: 83%DNASen: 76% Spe: 98%EBNA IgGSen: 83% Spe: 86%EBNA IgASen: 85% Spe: 86%Zta IgGSen: 79% Spe: 80%VCA IgA (1:10)Sen: 93% Spe: 87%3 ELISA combined(any two seropositivity)Sen: 92% Spe: 93%TKSen: 96% Spe: 96%VCA IgASen: 85% Spe: 98%EA IgASen: 72% Spe: 98%RtaSen: 82% Spe: 85%VCA IgASen: 84% Spe:98%EA IgASen: 96% Spe: 69%VCA IgASen: 87% Spe: 81%VCA IgGSen: 85% Spe: 54%EA IgASen: 58% Spe: 94%EA IgGSen: 70% Spe: 78%EA + EBNA1Sen: 98% Spe: 82%NPC pre-NPCVCA 74% 71%DNase (NT) 72% 86%DNase (ELISA) 82% 86%MDBP 82% 57%DP 71% 86%Sen Sensitivity; Spe specificity; AUC area under ROC curve; FA Fluorescence assay; ELISA enzyme-linked immunosorbant assay;NT neutralization test; PCR polymerase chain reaction